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The effectiveness of the Mitchell Method Relaxation Technique for the treatment of 
fibromyalgia symptoms: a randomised controlled trial 
 
Objective: To evaluate the effectiveness of the Mitchell Method Relaxation Technique (MMRT) in 
reducing symptoms of fibromyalgia. Design: A randomised controlled trial was used to compare the 
effectiveness of self-administered MMRT (n= 67) with attention control (n = 66) and usual care (n = 
56) groups. Main Outcome Measures: Primary outcomes included self-reported fatigue, pain, and 
sleep. Secondary outcomes were daily functioning, quality of life, depression, and coping, anxiety 
and perceived stress. Outcomes were assessed at baseline, post-intervention (four weeks) and follow-
up (eight weeks). Results:  A significant combined improvement on outcomes (p<.005), specific 
significant effects for sleep problems (d=0.29, p<.05), sleep inadequacy (d=0.20, p<.05), and fatigue 
(d=0.47, p<.05) were present in the MMRT group. At the follow-up, fatigue did not differ to the 
post-intervention score (p=.25) indicating short-term sustainability of the effect. The effects on sleep 
problems and sleep inadequacy were not sustained. The pain levels decreased when the MMRT was 
practiced three times a week (p<.001). Conclusion: MMRT was effective in reducing pain, sleep 
problems, and fatigue. High rates of relative risk reduction for fatigue (37%) and pain (42.8%) 
suggest clinical significance. 
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Abbreviations:  
PMR=Progressive Muscle Relaxation;  
MMRT=Mitchell Method Relaxation Technique;  
FIQR=Fibromyalgia Impact Questionnaire (Revised);  
MOS=Medical Outcome Sleep Scale;  
HADS-A=Hospital Anxiety and Depression Scale (Anxiety Subscale);  
HADS-D=Hospital Anxiety and Depression Scale (Depression Subscale); PSS=Perceived Stress 
Scale;  
VAS=Visual Analogue Scale;  
HRQoL=Health-related Quality of Life.   
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Introduction 
Fibromyalgia is a debilitating chronic condition, which is hallmarked by widespread pain, fatigue, sleep 
disturbance, and negative affect (Wolfe, Smythe, Yunus, Bennett, Bombardier, & Goldenberg, 1995). It is 
thought that 2 to 3% of the population experience this condition, although the prevalence rates are believed 
to be an underestimate (Bennett, Jone, Turk, Russell, & Matallana, 2007). The costs of health care for 
fibromyalgia are substantial (Berger, Dukes, & Oster, 2007). Currently, symptom management is the 
primary form of treatment, with pharmaceutical treatments commonly prescribed to reduce pain symptoms. 
Most medications, however, have adverse effects, which lead to the discontinuation of treatment, resulting 
in limited and non-sustained effect (Arnold, 2007). Multidisciplinary treatments, based on a 
biopsychological framework and aimed to address multi-domain symptoms of the condition, should form 
an important component of the treatment approach.  
The MMRT is an auditory relaxation technique, practiced individually and in silence. MMRT focuses on 
the psychoneuroimmunological link between mind and body, and incorporates guided imagery, muscular 
relaxation and breathing exercises, and implies full engagement and autonomy (Mitchell, 1997). The 
stress-related posture is thought to increase muscle tension and influence the nervous and endocrine 
systems as well as to cause muscle stiffness and dystonic patterns (Mitchell, 1990). Mitchell (1990) 
suggested that this method causes postural realignment by reversing stress-related posture. Findings from a 
systematic review of mind-body treatments for fibromyalgia suggest that guided imagery and progressive 
muscle relaxation (PMR) are efficient techniques for the management of the symptoms of fibromyalgia 
(Baranowsky, 2009). These techniques have been associated with a moderate positive effect on quality of 
life and a spectrum of fibromyalgia symptoms in two trials (Baranowsky, 2009). The MMRT has been 
found to reduce the physiological stress response in healthy adults, indicated by heart rate measurements 
(Bell & Saltikov, 2000). MMRT is a technique that can be taught and self-applied and therefore is very 
likely to have a long-lasting sustained positive effect on outcome measures. Coherent combination of 
imagery, muscular relaxation and breathing addresses the management of symptoms associated with FM. It 
is, therefore, expected, that the MMRT will diminish features of the condition that contribute to 
fibromyalgia symptomatology.   
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Many relaxation therapies involve prolonged therapy sessions, some taking a minimum of 45 minutes, 
during which patients have to be immobile. Considering that fibromyalgia patients report switching 
between relaxation and movement as one of the strategies they use to cope with pain (Theadom, Cropley, 
Humphrey, 2007), long immobility during these sessions may induce pain and hamper the therapeutic 
effect. In contrast, MMRT sessions are short, and therefore, the technique is expected to be more effective 
at symptom management and also less onerous for patients. In addition, to make the therapy acceptable for 
participants, we chose to deliver the study online. 
We propose that the MMRT will reduce fibromyalgia symptoms through its effect on the hypothesized 
underlying cause of the condition whilst the online delivery, self-application, and the short duration of each 
session reduce the burden on the fibromyalgia sufferers. In this RCT we examined the effectiveness of an 
online Mitchell Method Relaxation programme (Mitchell, 1997) in reducing fibromyalgia symptoms. The 
primary objective of this study was to evaluate the immediate effects of the MMRT on fibromyalgia 
symptoms and its short-term sustainability as well as to evaluate the dose-sensitive effect of the 
programme on health outcomes. The secondary objective was to identify its effects for subgroups of 
patients presenting with different co-morbidities, and to explore the mechanisms of the intervention. The 
third objective was to evaluate the clinical significance of the MMRT. 
Method 
Design 
A three-arm randomised controlled trial (RCT) was used to evaluate the effectiveness of the MMRT in 
comparison to active control and usual care groups. The study was conducted in accordance with the 
CONSORT Statement for RCTs of Non-Pharmacologic Treatments (Boutron, Moher, Altman, Schulz, & 
Ravaud, 2008) and, where applicable, with the CONSORT 2010 Statement (Schulz, Altman, & Moher, 
2010). The study was conducted online in England.  
Participants and Recruitment Procedure 
The study received ethical approval from the Faculty of Social Sciences, University of Surrey Ethics 
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Committee. Individuals diagnosed with fibromyalgia were approached online via regional support groups 
and 201 enrolled to participate in the study. Study participants gave their consent to take part in the current 
study via e-mail. To be eligible, participants had to meet the following criteria: aged between 18 to 80 
years, have Internet access and to be diagnosed with fibromyalgia syndrome as outlined by American 
College of Rheumatology classification criteria of widespread pain persistent for at least 3 months and 
tenderness at a minimum of 11 of the 18 tender points (Wolfe et al, 1995). Additionally, participants had to 
satisfy the new preliminary diagnostic criteria for fibromyalgia (Wolfe, Clauw, Fitzcharles, Goldenberg, 
Katz, & Mease, 2010). Internet connectivity across Great Britain is now widespread, with approximately 
83% having access to the Internet, and 73% of adults reporting use of the Internet every day. Internet 
connectivity is not confined to the more economically affluent groups (Office for National Statistics, 
2013). Participants reporting severe psychiatric comorbidities, life-threatening conditions, substance abuse 
and pregnancy as well as recipients of any non-pharmaceutical treatment were excluded from the study.  
To detect a medium effect size, using MANOVA with power of β=0.8 and to account for 20% dropout 
rate, 67 participants were recruited for each group. 
Health Outcomes and Measurements 
Primary Outcome Measures 
Pain Severity. To assess the severity of pain, a Visual Analogue Scale of Pain (VAS) was employed. VAS 
are widely used to assess pain in patients with fibromyalgia (Salaffi, Sarzi-Puttini, Ciapetti, & Atzeni, 
2009). The scale was adapted for online use and transformed from a 10 cm scale into 1-10 point scale. 
Lower VAS scores indicate lower level of pain severity.  
Sleep. The Medical Outcome Sleep Scale (Hays & Stewart, 1992) was employed to evaluate sleep quality. 
The MOS is a patient self-report sleep scale consisting of 12 items and is used to assess sleep across six 
domains: (1) sleep disturbance; (2) snoring; (3) awaking, due to shortness of breath or with a headache; (4) 
sleep adequacy; (5) somnolence; and (6), sleep quantity. The Sleep Problems Index summarizes responses 
using an abbreviated six-item index. This index contains questions from the sleep disturbance, sleep 
inadequacy, respiratory impairment, and somnolence domains, but not sleep quantity. Ten items of the 
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scale are scored using a six-point response scale, one item uses a five-point Likert scale, and sleep quantity 
is an open-ended question about the actual number of hours slept. Each subscale score and Sleep Problem 
Index range from a 0–100 scale and represents the percentage of a particular sleep domain; sleep quantity 
was recorded as 0–24 hours. Higher scores for the domains indicate worse sleep problems.  The MOS has 
good construct validity and reliability when used with fibromyalgia patients (Cappelleri, Bushmakin, 
McDermott, Dukes, Sadosky, Charles, Petrie, & Martin, 2009). The Cronbach’s α for each of the subscales 
was higher than .70 (Cappelleri, 2009). 
Fatigue. Levels of fatigue were assessed using fatigue subscale of the Short Form-36 Health Survey (Ware 
& Kosinski, 2001). The subscale is a sensitive, valid and brief measure of fatigue and consists of 4 items: 
(1) ‘Did you feel full of life?’, (2) ‘Did you have a lot of energy?’, (3) ‘Did you feel worn out?’, & (4) ‘Did 
you feel tired?’. The Likert scale for each item ranges from 1 (‘none of the time’) to 6 (‘all of the time’). 
The total score represents the sum of the scores for all items and ranges from 4 to 24, with a greater score 
representing higher levels of fatigue. The SF-36 fatigue scale is highly correlated with multidimensional 
fatigue, as measured by Fatigue Symptom Inventory Scale, r=-0.68 to -0.77 (Brown, Kroenke, Theobald, 
& Wu, 2011).  
Secondary Outcome Measures  
The impact of Fibromyalgia. The Revised Fibromyalgia Impact Questionnaire (FIQR; Bennett, Friend, 
Jones, Ward, Han, & Ross, 2009) was administrated to assess the components of health that are affected by 
fibromyalgia. The FIQR consists of 10 items constituting 3 dimensions: (1) ‘fibromyalgia symptoms’, (2) 
‘function’ and (3) ‘overall impact’. The FIQR is an advanced measurement in comparison to FIQ 
(Burckhardt, Clark, & Bennett, 1991), as it includes symptoms of tenderness and dyscognition and does 
not have sex or race biased items. The FIQR has desirable discriminant validity (Luciano, Aguado, & 
Seranno-Blanco, 2013). The Cronbach’s α value of the FIQR domains was higher than 0.80 (Bennet et al., 
2009). 
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Depression (Dysphoria). To assess depression (dysphoria) the Depression subscale of the Hospital Anxiety 
and Depression Scale was employed (Zigmond, & Snaith, 1983). Evidence of the discriminant validity, 
reliability of the measure in people with fibromyalgia has been demonstrated (Pallant, & Tennant, 2007). 
Anxiety. To assess the impact of treatment on the levels of negative affect, the anxiety subscale of the 
Hospital Anxiety and Depression Scale (Zigmond, & Snaith, 1983) was utilised. Greater score on HADS-
A indicates lower anxiety levels. 
Health-related Quality of Life. HRQoL was measured using SF-36 Health Survey (Ware & Kosinski, 
2001). SF-36 has a desirable reliability and has been validated for clinical samples. 
Coping. Coping difficulty and coping efficacy were assessed with two single items: ‘how difficult was it to 
cope with symptoms for the past week?’ and ‘How satisfied are you with how you coped with symptoms 
during the past week?’ respectively.  The items are valid measures of coping efficacy and coping difficulty 
with good reliability (Lazarus, & Folkman, 1983). 
Perceived Stress. The Perceived Stress Scale (PSS) was used to assess levels of perceived stress (Cohen, 
Kamarck, & Mermelstein, 1983). The PSS comprises of 10 items assessing the frequency of everyday 
stressful events and the perceived control of stressful event. PSS has been validated on a clinical sample of 
fibromyalgia patients. PSS construct and discriminant validity was reported. The scale has very good 
reliability, Cronbach’s α=0.78 [Cohen, & Williamson, 1988). 
To evaluate perceived effectiveness of the treatment intervention and the comparator, a Treatment 
Creditability Scale was utilised (Dunmore, 2001). The credibility scale asks participants to rate the logical 
approach of the treatment, the certainty that treatment will be successful and the degree of confidence with 
which to recommend the intervention to a friend. The items’ scale ranges from 0 (‘not at all’) to 10 
(‘completely’). The measurement of the dose comprised of the single item inquiring the frequency with 
which the intervention was applied. The item’s scale ranged from 1 (‘every day’) to 6 (‘less than once a 
week’).  To evaluate therapeutic effects of MMRT the assessment of outcome measures was performed 
three times: prior to the intervention treatment, immediately after a month of self-application, and at one-
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month follow-up. At the baseline assessment participants reported the comorbidities and demographic 
characteristics. 
Randomization 
Participants were allocated to one of the three study conditions in blocks of 30 in a 1:1:1 ratio. An 
algorithm implemented within the RandNum and SysRand functions, provided by the SSIWEB software, 
produced the automated random allocation to one of the groups. Participants were then able to download 
their allocated instructions from the next page on the website. Participants in the experimental condition 
were able to download instructions for the MMRT intervention, the attention control group were asked to 
listen to a relaxation audio recording and usual care participants were instructed to close the questionnaire.  
Treatments 
The Mitchell Method Relaxation Technique (MMRT) 
The intervention group received written instructions of the Mitchell Method Relaxation Technique 
(Mitchell, 1997) and a short (5 minutes 20 seconds) audio recording of the guided technique. Participants 
were asked to practice the MMRT by using the same audio recording every day for one month. When 
prepared and engaged, the participant sat at a desk or in a chair with a high back or laid on the floor. The 
participant was then given definite verbal orders (e.g. ‘move and feel’, ‘stop’, ‘feel’) to engage in a series 
of muscle relaxation exercises in the following sequence: arms, legs, body, head and face. Participants 
were not provided with training in discriminating between levels of muscle tension. Participants practiced 
muscle relaxation at their preferred level of tension to ensure autonomy – a key aspect of MMRT. After the 
completion of the exercise, participants engaged in deep breathing at a comfortable rate.  Lastly, the 
participant performed an imagery task, recalling a pleasant occasion or concentrating on a pleasant 
repetitive sequence (e.g. song, prayer) for one minute.  
The Attention Control 
The attention control group received an audio recording of ‘white noise’ and steady sound of resting heart 
rate (60 beats per minute) - imitation of ‘being in the womb’. Participants were instructed that regular 
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listening to the recording is deemed to initiate relaxation, increases sleep quality and reduces tension and 
stress, and subsequently reduces pain levels. Participants were asked to listen to the recording on a daily 
basis for one month. The length of recording was identical to the intervention. The mean total creditability 
score was not significantly different between participants who received the MMRT (M=6.02, SD=2.64) 
and participants who received the attention control treatment (M=5.30; SD=2.71), t (68) =1.10, p=.27), 
verifying the successful control for the placebo effect. Creditability score was not associated with health 
outcomes. Self-reports were employed to measure adherence to both, the MMRT and attention control, at 
post-intervention assessment and follow-up. 
Waiting list control 
Participants allocated to the waiting list group did not receive an active treatment and proceeded with usual 
care. All participants were offered the MMRT audio recording upon the completion of the study.  
Study Flow 
The flow chart (figure 1) presents process of the study, group allocation, excluded cases, and attrition rates. 
Dropouts resulted from the disregarding of e-mails, difficulty in contacting the participants, and 
withdrawals for personal reasons (i.e. holidays).  
Intention-To-Treat Procedure 
In accordance with the CONSORT statement for reporting randomised trials (Zwarenstein,  Treweek,  
Gagnier,  Altman, Tunis, Haynes, Gent, Oxman, & Moher, 2008), the statistical analysis was performed on 
the ‘intention-to-treat’ basis to avoid overestimation of clinical effectiveness and to control for bias 
introduced by participant dropout. All patients were included in the analysis, regardless of the treatment 
actually received and regardless of subsequent withdrawals or deviations from the protocol and loss to 
follow-up. Missing responses were imputed using multiple imputation procedure (Sterne,  Carlin,  Spratt,  
Royston,  Kenward,  Wood, & Carpenter, 2009). Linear regression analysis procedures were performed to 
determine the predictors of outcome variables. Co-morbidities, age, medication, and duration of the 
condition were significant predictors of baseline and post-treatment outcome measures. Therefore, to 
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preserve the naturally occurring trends in data the latter were stated as predictors in the linear regression 
model, used for multiple imputations. Due to reciprocal relationships between the outcome variables, all 
outcome measures were stated as predictors and used in the linear regression model for multiple 
imputations. The Rubin Rule of averaging on 5 sets of imputed data was performed to control for the 
uncertainty of the variance. Insignificant results of Little’s test confirmed the assumption that data-values 
were missing at completely random (MACR) [χ² (756; 58) = 84.153, p=1].  Differences between means of 
the observed and imputed data were insignificant based on a 95% confidence level.   
Participant’s characteristics and randomization check 
The age of participants ranged from 37 to 69 years. Participants were predominantly Caucasian (90%) and 
female (93.7%). The demographic characteristics are presented in Table 1. Frequencies of co-morbidities 
and gender distribution across groups are representative of the fibromyalgia population. To verify the 
randomisation and equal distribution of baseline characteristics between the three groups, the χ² test was 
performed on the categorical variables and MANOVA on the continuous variables. The groups did not 
differ in terms of distribution of males and females [χ² (2; 191) =.888, p=.642]. The frequencies of Restless 
Leg Syndrome [χ²(2;191)=2.26, p=.323], Asthma [χ² (2;191)=2.52, p=.882], Chronic Fatigue Syndrome 
[χ²(2;191)=816, p=.665], Sleep Apnoea [χ² (2;191)=4.48, p=.107] , depression and other co-morbidities 
[χ²(2;191)=3.40, p=.183] were the same across the study groups. The three groups did not differ in terms of 
age [F(2; 191) =.834, p=.436] and diagnosis duration [F(1,191) = 2.76, p =.070]. Using Pillai’s trace, 
MANOVA indicated, that at baseline, overall variances across all outcome measures was not significantly 
different across three study groups [V=.328, F (54; 326) =1.186, p=.187, β=.991]. However, follow-up 
univariate between-subjects ANOVA demonstrated the significant difference in the mean VAS pain score 
at the baseline [F (2; 188) =3.08, p=.05]. Post hoc multiple comparisons with Tukey’s adjustment 
identified that the mean value of the baseline VAS pain score of the MMRT group (M=7.43, SD=1.68) 
was significantly higher than the mean value of the waiting list control group [(M=6.68; SD=1.42), p<.05]. 
The somnolence baseline scores significantly differed across the three groups [F (2; 188) =3.50, p<.05]. 
The mean baseline somnolence score of the MMRT group (M=55.19; SD=27.74) was significantly higher 
than the mean score for the control group (M=46.80; SD=33.86), p<.05). The baseline mean scores of 
FIQR, HRQoL, sleep dimensions, anxiety, dysphoria, perceived stress, coping efficacy and coping 
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difficulty did not differ across the groups.  
Statistical Analysis 
Evaluation of the immediate effects of the treatment  
The researchers performed blinded analysis of the data. Two-tailed hypothesis tests were employed 
throughout the analysis. Between-subject MANCOVA was employed to test the differences between 
groups on the extent of change among outcome variables, after having adjusted for pre-intervention levels. 
MANCOVA, in contrast to several ANOVAs, accounts for multivariate relationships between pain, sleep, 
fatigue, and other outcomes. Using Levine’s Test of Equality of Error Variance, the assumption of 
homogeneity of variance was supported, indicating the robust multivariate analysis. The baseline measures 
for all outcomes were included as covariates due to significant differences in baseline VAS score and 
somnolence scores across groups and its reciprocal relationships with other primary and secondary 
outcome measures. Age, medication, co-morbidities, and diagnosis duration were included as covariates, to 
control for its predictive value identified at the preliminary analysis. To provide accurate estimates of the 
effect sizes for the population Cohen’s ds were calculated. MANCOVA was followed up with discriminant 
function analysis to test the differences between study conditions and to explore the covariance between 
changes in outcome variables.  
Evaluation of the sustained effects of the treatment 
A treatment (MMRT, Attention Comparator, Control Group), by time (baseline, post-intervention, one 
month follow-up) Mixed-Subject MANOVA was conducted to evaluate the effect of the intervention 
against the attention group and the waiting list control group. Due to the significant results of Mauchley’s 
test and the violated assumption of sphericity for sleep inadequacy scores [χ² (2) =30.3, p<.001], sleep 
problems scores [χ² (2) =22.87, p<.001] and fatigue scores [χ² (2) =1.81, p<.05] the Greenhouse–Geisser 
corrected values are presented. The differences between the groups are assessed by planned comparisons 
and differences across time are assessed using Bonferroni adjustments.  
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Evaluation of effects for subgroups, dose-sensitive effects and mechanisms of the treatment 
Bootstrapping method of simple moderation analysis was performed (Hayes, 2009; 2012; 2013) to 
test for moderating effect of comorbidity (i.e. RLS) on the effectiveness of the MMRT and the 
conditional effect of the MMRT at a value of dose. A presence of comorbidity was coded as 1 and its 
absence was coded as 0.  Multiple mediation analysis (Preacher & Hayes, 2008) to test for the indirect 
effects of the intervening variables was performed.  
The clinical significance of the treatment 
The clinical significance of the treatment is presented by taking into account: the Absolute Risk Reduction 
(ARR), Relative Risk Reduction (RRR), Number Needed to Treat (NNT), Cohen’s U3, and Probability of 
the Superiority. The ARR is an arithmetic difference between experimental group and the control group in 
percentages of participants who displayed the reduction in the outcome scores after the treatment. The 
RRR is based on the relative percentage of participants who benefited in terms of each outcome in 
comparison to control groups. NNT was calculated using the following formula: 1÷ Ö (Cohen’s 
d−1÷(CGP))−CGP, where Ö is the cumulative distribution function of the standard normal distribution; 
CGP is the control group's percentage of people displaying symptom reduction in the control group; and ä 
- the population Cohen's d. U3 was calculated by multiplying cumulative distribution function (Ö) by 
Cohen’s d. Probability of the Superiority was calculated using the following formula:  Ö(Cohen’s d ÷√2). 
Results 
Immediate effects of the MMRT 
MANCOVA, using Pillai’s trace, identified a significant groups and pre-post interaction across all 
outcomes [V=.511, F (56; 266) =1.631, p<.005, η²=.256]. Summary of mean scores before and after the 
intervention, together with effect sizes at 95% confidence level for all variables are presented in Table 2. 
Separate univariate ANCOVAs on the outcome variables revealed significant difference across the groups 
in mean changes of sleep problems [F(2;159)=3.70, p<.05, ηp²=.044], sleep inadequacy [F(2;159)=3.09, 
p=.048, ηp²=.037], anxiety [F(2;159)=3.22, p<.05, ηp²=.039], and fatigue  [F(2;159)=4.633, p<.05, 
ηp²=.055]. The confidence intervals of effect sizes on the primary outcomes are presented in Table 3.  
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The mean pre-post change of perceives stress score (PSS) did not significantly differ across three study 
arms [F (2; 159) =2.27, p=.11, ηp²=.027]. Similarly, the treatment effects on sleep disturbance [F (2; 156) 
=.924, p=.39, ηp²=.011] and sleep initiation [F (1; 159) =2.15, p=.12, ηp²=.026] were insignificant. The 
mean changes of the VAS score across three groups did not significantly vary [F (2; 159) =.536, p=.592, 
ηp²=.007]. Univariate ANCOVAs did not detect significant differences between the study groups in mean 
pre-post changes of the secondary outcome variables (Table 2).  
MANCOVA was followed-up with one way between-subject analysis of variance of fatigue, anxiety, sleep 
problems, sleep inadequacy, controlling for baseline measurements, age, medication, duration of diagnosis 
and comorbidities. Planned contrasts revealed that the average pre-post change of fatigue score in the 
MMRT was significantly different from the mean change of the score in the control [t (160) =2.16, p<.05], 
and attention comparator [t (160) =6.32, p<.05] groups. The attention comparator group’s pre-post change 
in fatigue score was not significantly different from the mean of the control group [t (160) =-.223, p=.823]. 
The mean pre-post change in levels of anxiety for the attention comparator group was significantly higher 
than the mean for the wait-list control group [t (160) =2.50, p<.05]. However, the anxiety levels in the 
main intervention group did not significantly drop in comparison to the control group [t (160) =.885, 
p=.38]. Sleep inadequacy was significantly reduced for MMRT group when comparing to waiting list 
control group, [t (160) =-2.56, p=.01], but did not significantly differ from the attention comparator group 
[t (160) =6.97, p=.188]. Sleep problems were reduced after the MMRT significantly more than in attention 
control [t (160) =8.37, p<.01], and waiting list groups [t (160) =2.36, p<.02].  
MANCOVA was additionally followed up with discriminant function analysis to explore whether the 
MMRT group membership significantly predicted the pre-post intervention change across outcomes. The 
first discriminant function explained 63.4% of the variance (canonical r²=.25). Change in scores on sleep 
inadequacy (r=.377), sleep problems (r=.491) and fatigue (r=.456) loaded significantly high on the first 
function. The first discriminant function significantly differentiated the MMRT group from the attention 
comparator and control groups, [Λ=.807, χ²(12)= 39.72, p<.001].  The second function explained 36.6 % 
of variance (canonical r²=.277) and was correlated with pre-post change in anxiety levels (r=.30). The 
second function significantly differentiated control group from both active groups, [Λ=.923, χ² (5) =14.79, 
p<.01]. Therefore, the MMRT group demonstrated significantly greater reduction of fatigue, sleep 
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problems and sleep inadequacy scores relative to the control and usual care groups. Whilst, the active 
control’s group mean pre-post change in anxiety was significantly different to usual care.  
Effects of the MMRT at one-month follow-up 
Mixed Subject MANOVA indicated the significant effect of time on all outcome measures within the 
entire cohort [V=.959, F (2; 137) =62.02, p<.001, η²= .059]. Overall, the outcome measures significantly 
differed across the three study arms over time [V=.735, F (2; 276) =1.54, p<.005, η²=.368]. However, the 
effect of attention comparator group on the anxiety levels was not sustained at the follow-up [F (4; 376) 
=1.61, p=.171].  
Sleep Inadequacy 
Mean scores of sleep inadequacy at three time points were significantly different across the groups [F 
(3.81; 376) =2.895, p<.05]. The planned contrast comparison indicated significant difference between post-
intervention mean scores and the follow-up mean scores [F (2; 376) =4.89, p<.01]. However, the mean 
scores at one-month follow-up did not differ from the score assessed at the baseline [F (2; 376) =673, 
p=.512]. The latter suggests that the effect of the intervention on sleep inadequacy did not sustain at the 
follow-up.  
Sleep Problems  
Mean scores of sleep problems (MOS) significantly varied across assessment points between the groups [F 
(3.59; 376) =2.79, p<.05, η²= .030]. Within subject contrasts indicated significant difference between mean 
scores at baseline and post-intervention [F (2; 376) =2.83, p<.05]. However, the follow-up mean score of 
the MMRT group (M=51.11; SD=13.16) was significantly higher than the post-intervention mean score 
(M=46.46 SD=14.16), [F (2; 376) =4.50, p<.05]. Therefore indicating, that sleep problems score regressed 
to the baseline score.  
Fatigue 
There was a significant interaction between the groups and time [F (3.81; 376) = 2.812, p<.05, ηp²=.033]. 
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Planned within-subject contrasts with Bonferroni adjustment showed that the follow-up MMRT fatigue 
score was significantly lower than baseline scores [F (2;356)=3.182, p<.05], however, did not differ from 
the fatigue levels as measured immediately after the intervention [F(2;356)=1.415, p=.246], indicating the 
sustained effect of MMRT on fatigue levels.  
Dose-sensitive effects of the MMRT 
The mean value of dosage was 3.5 (SD=1.27), which corresponds to 5 sessions a week. A significant dose-
conditioned effect of the intervention on the VAS score was observed [R=.24, F (3; 132) =3.44, p<.05; 
interaction B=-.72, t=-2.97, p<.005]. At the value of dose = 4.77, which corresponds to 3 sessions a week, 
[t (049) = 2.10, p<.05].  The VAS score was significantly reduced by .55 when the technique was practiced 
at least 3 times a week. The mean pre-post changes in VAS scores at a value of dose are presented in figure 
2.  Dose of the intervention did not have a moderating effect on any other outcome variables. The dose was 
significantly reduced by a value of 3.37 at the follow-up assessment [t(190)=36.37, p<.001; CI: 3.18; 
3.55].  
MMRT effects for clinical subgroups 
Restless Leg Syndrome (RLS) did not have a significant moderating effect on pre-post change in sleep 
inadequacy, sleep problems and fatigue as evaluated by bootstrapped moderated mediation model [R=.11, 
p=.97; interaction B=6.19, t(.48)=1.29, p=.20]. The independent t-test identified significant difference [t 
(65) =-2.08, p<.05] between mean pre-post changes in sleep problems score for the participants’ with co-
morbid RLS (M=7.20; SD=18.19) and those without the co-morbidity (M=- 6.6; SD=21.49). Similar 
results were observed in coping difficulty [t (65) =2.40, p<.05]. Participants with RLS co-morbidity 
experienced small increase in coping difficulty (M=.14, SD=.21), whereas participants without comorbid 
RLS displayed decrease in coping difficulty (M=-.81; SD=1.39). The effects however, were not significant 
when compared to the control groups. Frequencies of other comorbidities were too low to conduct the 
moderation analysis. 
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The mechanism of the MMRT 
The mediating roles of sleep problems and sleep inadequacy were tested. The total effect of the MMRT 
and the indirect factors explained 34.4% of the change in the variance of fatigue, and sleep inadequacy, 
and sleep problems, explained 14.7% of the unique variance in fatigue change [R=.344, R²=.118, 
F(3;187)=8.37, p<.001]. However, only sleep problems had a significant mediating effect on fatigue 
(figure. 3). No other significant mediators were identified.  
The clinical significance of the MMRT 
Table 4 presents Absolute Risk Reduction (ARR), Relative Risk Reduction (RRR), and Number Needed to 
Treat (NNT) for the MMRT group comparatively to the waiting list control group. As indicated by 
Cohen’s U3, the 70.54% of the individuals who received MMRT had greater reduction in pain severity than 
the mean reduction rate in usual care group.  The percentages for sleep inadequacy; sleep problems, and 
fatigue are given in Table 4. Given overall improvement in both control and treatment groups, the 
probabilities of a person selected at random from the MMRT group having a larger reduction in pain 
severity (64.87%) fatigue (63.02%), sleep problems (58.12%), and sleep inadequacy (55.62%) than a 
person selected at random from the control group, are relatively large. 
Discussion 
This is the first study to evaluate the effectiveness of the Mitchell Method Relaxation Technique in 
reducing symptoms associated with fibromyalgia. The results showed a dose-response effect on pain 
levels, moderate sustained effect on fatigue, and short-term positive effect on sleep quality. Thus, the 
MMRT is effective at reducing fatigue, sleep problems, and in particular, sleep inadequacy for people with 
fibromyalgia. Furthermore, the technique effectively reduces pain severity, if practiced at least 3 times a 
week. However, practicing the MMRT did not improve functioning, depression (dysphoria), HRQoL or 
coping with the condition.  
Fatigue and poor sleep emerge as the most prominent problems of fibromyalgia experience and have been 
reported by patients as being more detrimental than pain (Bennet et al., 2007) yet, treatments targeting 
fatigue and sleep in patients with fibromyalgia are in shortage (Cropley & Theadom, 2008). Although 
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existing mind-body interventions decreased pain levels, improved mood and functioning in short-term did 
not result in improved sleep quality or decreased fatigue levels (Theadom et al., 2015). Whilst the MMRT 
significantly attenuated sleep problems and fatigue prevalent in fibromyalgia. Furthermore, the positive 
effect of the MMRT on fatigue persisted a month later. Therefore, the MMRT is a favourable symptom 
management aid for fibromyalgia-related fatigue and sleep problems compared to other existing mind-
body therapies.  
The results revealed that improvement in sleep quality significantly accounted for the reduction in fatigue 
levels induced by the MMRT. The latter is in line with the evidence supporting the moderating role of poor 
sleep in fatigue (Nicassio et al., 2002). In conjunction with insignificant mediating effect of pain on fatigue 
levels, this points out the primary causal role of sleep problems in fibromyalgia-related fatigue.  
Identification of subgroups of patients is an important factor of the treatments’ effectiveness particularly 
for patients with fibromyalgia (Adams & Sims, 2005). We used the bootstrapped method in the present 
study to evaluate the moderating role of comorbid RLS on the MMRT effect. The effectiveness of the 
MMRT for the subgroup of patients displaying RLS co-morbidity was however not supported. Thus, the 
effects of the MMRT, as well as effects of other treatments, for different clinical subgroups of 
fibromyalgia patients should be investigated in studies with a larger sample size.  The presence of RLS 
causes sleep difficulties (Allen, Walters, Montplaisir, Hening, Myers, Bell, & Ferini-Strambi, 2005), in 
addition to the normal sleep problems accompanying fibromyalgia, and thus, conflicts with the MMRT’s 
effects on sleep. This suggests a need for specific symptom management for patients with comorbid 
dystonic patterns.  
Future studies of the effectiveness of the MMRT are urged to assess the long-term effects. The long-term 
effect is not reflected in the current study, due to the reduced adherence to the intervention as assessed at 
the one-month follow-up. The MMRT can be easily learned and self-applied, and therefore likely to have 
long-term therapeutic effects with sustained practice.  Perhaps educating patients of the benefits of 
continuing with the technique would increase adherence and practice long-term. The issue of treatment 
adherence should be addressed by future research in order to increase the sustainability of the MMRT’s 
corrective effect on fibromyalgia symptoms.  
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The intervention was self-applied and delivered online, and this may have contributed to the dropout rate, 
and perhaps this could have been reduced if there was regular contact with a health professional. It is 
expected that MMRT will have a greater sustained effect on health outcomes if implemented in clinical 
settings or under therapist’s supervision. In addition, the limitations of the study include self-reported 
measures of compliance, which could be overcome by direct observations in clinical settings.  On the other 
hand, the online delivery, self-application and minimal intrusion throughout the study, provides evidence 
of the MMRT effectiveness in real world settings, thus increasing the ecological validity of the findings. In 
addition, patients with fibromyalgia may prefer interventions that they can practice at home, and this 
would increase their perceptions of control over their condition, and also will help to avoid the necessary 
travel to the clinic, which patients could find challenging. Furthermore, the nature of the technique and the 
session’s short duration accommodate for the patients’ need to shift between movement and immobility. 
Comparative studies are required to determine the constructive modes of delivery and duration of sessions.  
Several measures were taken to obtain an objective assessment of the technique. The study included a 
representative homogeneous sample of fibromyalgia patients. The selection bias was eliminated by 
randomisation procedure. Furthermore, the blinding of the assessors of the outcomes was performed. 
Additionally, the potential biases introduced by the high attrition rates were reduced through the 
employment of intention-to-treat analysis. The significantly greater improvement of the MMRT group in 
comparison to attention control group, as indicated by the discriminant function analysis, supports the 
specific effect of the intervention and accounts for the unspecified placebo effect. The rigorous method of 
this study helps to ascertain objective evaluation of the MMRT effectiveness.  
The MMRT fulfils few of the criteria for clinical significance. Firstly, The MMRT effect on pain and 
fatigue was relatively large, 42.84% and 37%, respectively. Secondly, the estimate of the Number Needed 
to Treat (NNT) is 4.74 for pain and 5.38 for fatigue. The NNT of 2-5 is considered indicative of the 
clinically effective treatment in pharmaceutical research (Cook & Sackett, 1998). Furthermore, none of the 
study participants reported adverse effects of the treatment. Stringent control for biases as well as a 
relatively small NNT, large magnitude of the effects and absence of health hazards advocate the clinical 
importance of the MMRT for fatigue and pain levels attenuation. 
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In summary, the Mitchell Method Relaxation Technique attenuates sleep inadequacy, sleep problems, and 
subsequently fatigue, and pain in patients with fibromyalgia. This symptom management does not require 
substantial effort and commitment. The technique, therefore, is a feasible and cost-effective management 
of fibromyalgia symptoms in patients without comorbid RLS. This study highlights the role of effective 
management of sleep problems in the fibromyalgia treatment approach. The absence of adverse effects, 
rigorous methods of evaluation and the supported effectiveness in symptoms management, signify the 
MMRT as an adjuvant treatment for the individuals diagnosed with fibromyalgia.  
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Figure 1. Participants flow chart according to the revised CONSORT statement (2001).  
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Figure 2. Dose-conditioned mean pre-post change of VAS score. 
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Figure 3. The MMRT mechanism, being tested on the basis of the multiple mediator model (Preacher, & 
Hayes, 2008).  
 
 
 
 
 
   
Sleep Problems (MOS) 
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   b=-5.90, p=.047        b=-.28, p=.001 
b=-.4.90, p=.006 
Indirect effect: b=-.785, 95%  
CI [-2.29; -.08] 
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Table 1. Baseline characteristics of the three study groups 
 MMRT           Attention  
Control  
Waiting List 
Age 48.10 ±11.08  50.46±10.75 48.95±10.13 
 
Gender 
63 Females 
4 males 
 
63 Females 
3 males 
53 Females 
5 males 
Diagnosis duration (years) 11.61±6.99 14.09±9.56 10.97±6.77 
Restless Leg Syndrome 17.9% 24.2% 13.8% 
Asthma 9% 6.9% 9.1% 
Chronic Fatigue Syndrome 3% 4.5% 1.7% 
Sleep Apnea 6% 0% 6.9% 
Depression 10.4% 9.1% 6.9% 
Other co-morbidities 68.7% 54.5% 67.2% 
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Table 2. Means and standard deviations for all variables per group at baseline (pre) and at the end of the intervention (post). 
 MMRT (N=67) Attention Control 
(N=66) 
Waiting List (N=58) 
 Pre Post Pre Post Pre Post Par.ƞ² d p 
VAS 7.44±1.69 7.03±1.81 7.26±1.74 7.26±2.03 6.70±1.42 6.87±1.69 .017 0.54 .59 
Sleep problems index 49.50±16.88 46.46±14.16 50.48±18.44 54.40±18.76 54.86±15.10 55.73±14.71 .044 0.29 .03 
Sleep initiation 3.33±0.17 3.00±0.20 2.90±0.17 2.94±0.17 3.26±1.80 3.31±1.90 .026 0.22 .12 
Sleep disturbance 38.05±2.32 42.16±2.89 37.4±2.60 37.70±2.48 41.77±2.51 42.22±2.72 .011 0.16 .39 
Sleep inadequacy 85.53±20.89 76.57±20.89 87.03±20.14 87.28±25.76 87.96±17.50 89.63±25.19 .037 0.20 .05 
Sleep quantity 5.95±0.22 6.00±0.18 6.18±0.22 5.96±0.15 6.16±0.25 5.89±0.26 .001 0.28 .70 
Fatigue (SF-36) 20.47±17.09 18.73±15.87 15.45±16.23 19.09±11.89 16.98±17.04 20.88±15.35 .055 0.47 .01 
PSS 22.64±0.95 18.89±0.89 23.40±0.94 20.67±0.80 23.10±0.82 19.98±0.86 .027 0.10 .11 
HADS-A* 9.72±3.56  10.00±4.09       9.61±3.38         10.50±3.96        10.28±2.97           9.73±3.33 .039 0.07 .04 
HADS-D 10.40±0.27 10.40±0.46 9.62±0.26 9.73±4.60 10.06±0.31 10.50±0.40 .015 0.17 .30 
HRQoL 29.80±17.27 31.20±19.45   32.37±21.78 29.21±22.67 29.84±18.87 26.50±20.48 .012 0.01 .157 
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Note: Greater score on HADS-A indicates lower anxiety levels. Greater scores for all other variables correspond to higher levels of the outcomes. Cohen’s d reflects 
difference between mean pre-post changes of MMRT and waiting list groups divided by pooled standard deviations. P values represent between groups difference of 
within-group mean pre-post change, controlling for baseline outcome measures and characteristics using MANCOVA. 
 
FIQR 68.09±20.03 68.79±16.90 69.83±20.67 68.72±17.88 65.50±16.10 66.10±15.34   .001 0.24 .708 
Coping difficulty  3.54±1.00 3.47±0.96 3.65±1.05 5.21±3.48 3.35±0.94 3.29±1.00 .013 0.56 .148 
Coping efficacy 3.30±1.17 2.49±9.33 3.20±1.13 2.37±0.87 2.98±1.00 2.41±1.00 .019 0.33 .075 
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Table 3. The estimation of the mean pre-post change in the scores (95 % CI).  
 MMRT Attention Control 
Sleep problems index [-14.13;-0.99] [-5.98;7.05] 
Sleep inadequacy [-24.01; -2.75] [-17.33;3.75] 
Fatigue [-15.98;-2.34] [-6.78;6.07] 
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Table 4. Clinical significance of the MMRT for fatigue, sleep problems, sleep inadequacy, and pain comparing to waiting list (WL). 
  ARR (%)  RRR (%) NNT U3 (%) 
Probability 
of 
superiority 
(%) 
SF-36 
Fatigue 
15.3 37 5.38 68.08 63.02 
Sleep 
Problems  
15.4 26.7 9 61.41 58.12 
Sleep 
Inadequacy  
3.6 4.9 16.34 57.93 55.62 
VAS 14.77 42.84 4.74 70.54 64.87 
 
 
 
 
 
 
